| Date | Title | Description | Source |
| 25.04.2024 | 1st Quarter Results | 1st Quarter Results
Thu, Apr 25, 2024 08:00 CET Report this content
AstraZeneca
25 April 2024
Q1 202... | news.cisio... |
| 25.03.2024 | AstraZeneca to Acquire Fusion Pharmaceuticals, for Up To $2.... | AstraZeneca (LSE/STO/Nasdaq: AZN) has entered into a definitive agreement to acquire Fusion Pharmace... | finsmes.co... |
| 21.03.2024 | AstraZeneca Acquires Fusion Pharmaceuticals for $2B to Bolst... | What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmace... | hitconsult... |
| 19.03.2024 | AstraZeneca to acquire Fusion | AstraZeneca to acquire Fusion
Tue, Mar 19, 2024 08:00 CET Report this content
19 March 2024
AstraZen... | news.cisio... |
| 19.03.2024 | AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion Ac... | AstraZeneca is following in the footsteps of some of its big pharmaceutical company peers, plunking ... | medcitynew... |
| 19.03.2024 | Astrazeneca expands cancer treatment stable with purchase of... | Pharmaceutical giant Astrazeneca is expanding its cancer treatment capabilities through the acquisit... | cityam.com... |
| 03.05.2023 | Fusion Pharmaceuticals Announces Opening Of Radiopharmaceuti... | HAMILTON, ON, May 2, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stag... | healthcap.... |
| 21.04.2023 | Fusion Pharmaceuticals Announces Presentation Of Preclinical... | FPI-2059 induces tumor growth inhibition in colorectal tumor model
TEM-1 and EGFRvIII demonstrate p... | healthcap.... |
| 14.04.2023 | Fusion Pharmaceuticals Announces IND Clearance For FPI-2068,... | FPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tum... | healthcap.... |
| 12.04.2023 | Fusion Pharmaceuticals Announces IND Clearance For FPI-2068,... | Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing ... | lumiravent... |
| 22.03.2023 | Fusion Pharmaceuticals Announces First Patient Dosed In Phas... | HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a... | healthcap.... |
| 16.03.2023 | Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financi... | Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a sm... | healthcap.... |
| 15.02.2023 | Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-... | Hamilton, ON, Canada and Boston, MA, USA. 13 February 2023. Fusion Pharmaceuticals Inc. (Nasdaq: FUS... | seroba-lif... |
| 07.01.2023 | Fusion Pharmaceuticals And BWXT Medical Announce Actinium-22... | – Agreement augments Fusion’s existing isotope supply as pipeline of clinical stage actinium-based r... | healthcap.... |
| 09.11.2022 | Fusion Pharmaceuticals Announces Third Quarter 2022 Financia... | FPI-1434 Phase 1 data on track to be reported in first half of 2023
Phase 1/2 Study of FPI-1966 ope... | healthcap.... |
| 08.11.2022 | Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. As Chie... | Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing ... | lumiravent... |
| 30.08.2022 | Fusion Pharmaceuticals Announces First Patient Dosed In Phas... | HAMILTON, ON and BOSTON, Aug. 29, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a ... | healthcap.... |
| 11.08.2022 | Fusion Pharmaceuticals Announces Second Quarter 2022 Financi... | FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted al... | healthcap.... |
| 22.06.2022 | Fusion Pharmaceuticals Presents Imaging Data From Cold Antib... | Hamilton, Ontario, Canada and Boston, USA. 14 June 2022. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN),... | seroba-lif... |
| 09.02.2022 | Fusion Pharmaceuticals Announces Inducement Grants Under Nas... | HAMILTON, ON and BOSTON, Feb. 9, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a ... | marketscre... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. As Se... | HAMILTON, ON and BOSTON, Sept. 21, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Enters Into Agreement To Build Radiop... | HAMILTON, ON and BOSTON, June 2, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a c... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Third Quarter 2021 Financia... | FPI-1434 Phase 1 multi-dose data now expected in 2H 2022
FPI-1966 Phase 1 study initiated; first pa... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Announces First Quarter 2021 Financia... | Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022
Continuing expan... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Mohit Rawat As President And... | HAMILTON, ON and BOSTON, Sept. 28, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Announces FDA Clearance Of IND For FP... | HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a ... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Industry Veteran Christopher... | – Eric Burak, Ph.D. Appointed as Chief Technology Officer
HAMILTON, Ontario and BOSTON, Nov. 2, 202... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Clinical Collaboration With... | HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a cl... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Second Quarter 2021 Financi... | Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Presentation Of Preclinical... | Single and multiple doses of FPI-1966 demonstrated therapeutic efficacy in a preclinical bladder xen... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals And TRIUMF Announce Expanded R&D ... | Fusion and TRIUMF to collaborate to produce actinium based on technology developed by TRIUMF
HAMILT... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. As ... | HAMILTON, ON and BOSTON, June 7, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a c... | healthcap.... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Preliminary Safety And Dosi... | Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable sa... | healthcap.... |
| 09.11.2021 | Fusion Pharmaceuticals Announces Third Quarter 2021 Financia... | FPI-1434 Phase 1 multi-dose data now expected in 2H 2022
FPI-1966 Phase 1 study initiated; first pat... | marketscre... |
| 31.08.2021 | Fusion Pharmaceuticals Announces Inducement Grants Under Nas... | | prnewswire... |
| 10.08.2021 | Fusion Pharmaceuticals Announces Second Quarter 2021 Financi... | | prnewswire... |
| 10.08.2021 | Fusion Pharmaceuticals : Announces Second Quarter 2021 Finan... | Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022... | marketscre... |
| 29.07.2021 | Fusion Pharmaceuticals Announces FDA Clearance Of IND For FP... | HAMILTON, ON and BOSTON, July 28, 2021 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stag... | lumiravent... |
| 28.07.2021 | Fusion Pharmaceuticals : Announces FDA Clearance of IND for ... | HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a... | marketscre... |
| 28.07.2021 | Fusion Pharmaceuticals Announces FDA Clearance of IND for FP... | | prnewswire... |
| 07.07.2021 | Fusion Pharmaceuticals Announces Inducement Grants Under Nas... | | prnewswire... |
| 14.06.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Announ... | Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable sa... | marketscre... |
| 14.06.2021 | Fusion Pharmaceuticals Announces Preliminary Safety and Dosi... | | prnewswire... |
| 11.05.2021 | Fusion Pharmaceuticals Announces First Quarter 2021 Financia... | | prnewswire... |
| 06.05.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Announ... | HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a c... | marketscre... |
| 06.05.2021 | Fusion Pharmaceuticals, Lumira Portfolio Company, Announces ... | HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a cl... | lumiravent... |
| 06.05.2021 | Fusion Pharmaceuticals Announces Clinical Collaboration with... | | prnewswire... |
| 29.03.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Corpor... | Corporate Presentation
March 2021
Forward-Looking Statements and Legal Disclaimers
This presentation... | marketscre... |
| 25.03.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Announ... | - FPI-1434 Phase 1 study is progressing
- Recent transactions and partnerships expand and diversify ... | marketscre... |
| 25.03.2021 | Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financi... | | prnewswire... |
| 02.03.2021 | Fusion Pharmaceuticals to Expand Pipeline with Acquisition o... | Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emittin... | lumiravent... |
| 10.02.2021 | Discover the Medical Isotope & Radiopharmaceutical Lands... | Did you know that Canada has been a global leader in the research, development and production of med... | admarebio.... |
| 10.11.2020 | Fusion Pharmaceuticals Announces Third Quarter 2020 Financia... | | prnewswire... |
| 02.11.2020 | Fusion Pharmaceuticals Announces Collaboration with AstraZen... | | prnewswire... |
| 13.01.2020 | Precision oncology startup Fusion Pharmaceuticals raises $26... | Biopharmaceutical precision oncology startup Fusion Pharmaceuticals has received a commitment of up ... | betakit.co... |
| 15.04.2019 | Hamilton biopharmaceutical raises $140 million CAD for cance... | Hamilton-based biopharmaceutical company Fusion Pharmaceuticals has announced the completion of a $1... | betakit.co... |
| 04.04.2019 | What Happens When ‘Fake It Till You Make It’ Goes Too Far: T... | SECOND ACT
If you read the book Bad Blood or watched the HBO documentary The Inventor, both of which... | fortune.co... |
| 02.04.2019 | Fusion Pharmaceuticals Raises $105 Million in Oversubscribed... | BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals, a clinical-stage biopharmac... | citybizlis... |
| 02.04.2019 | Fusion Pharmaceuticals Raises $105 Million in Oversubscribed... | BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals, a clinical-stage biopharmac... | archive.ci... |
| 02.04.2019 | Fusion Pharmaceuticals Raises $105M in Series B Financing | Fusion Pharmaceuticals, a Hamilton, Ontario, Canada and Boston, MA-based clinical-stage biopharmaceu... | finsmes.co... |
| 01.04.2019 | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed... | - | orbimed.co... |
| 23.02.2018 | Seeking greater gender diversity, Alnylam promotes f... | Leila Jalinous
→ Consistent with a goal to foster gender diversity in its leadership ranks... | endpts.com... |
| 26.09.2017 | Term Sheet — Tuesday, September 26 | FRESH FUNDING
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyb... | fortune.co... |
| 25.09.2017 | Fusion Pharmaceuticals Completes Oversubscribed Series A Fin... | - | jnjinnovat... |
| 25.09.2017 | Fusion Pharmaceuticals Secures Additional $21M; Closes $46M ... | Fusion Pharmaceuticals, a Hamilton, Canada-based clinical-stage biopharmaceutical company developing... | finsmes.co... |
| 25.09.2017 | Fusion Pharmaceuticals Completes Series A Financing Totaling... | HAMILTON, Ontario–(BUSINESS WIRE)–September 25, 2017–
Fusion Pharmaceuticals, a clinical-stage bioph... | venturebea... |
| 23.02.2017 | FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A L... | - | jnjinnovat... |
| 23.02.2017 | Fusion Pharmaceuticals Launches with USD$25M Series A Financ... | Fusion Pharmaceuticals, a Hamilton, Ontario, Canada-based biopharmaceutical company developing targe... | finsmes.co... |
| 23.02.2017 | Fusion Pharmaceuticals Launches with a $25M USD Series A Fin... | HAMILTON, Ontario–(BUSINESS WIRE)–February 23, 2017–
Fusion Pharmaceuticals, a newly formed biopharm... | venturebea... |
| - | Fusion Pharmaceuticals Announces Appointment of Steven Ganno... | Boston, MA & Hamilton, ON – March 4, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncolo... | healthcap.... |
| - | Fusion Pharmaceuticals Presents Imaging Data From Cold Antib... | – Study evaluates pre-administration of cold antibody prior to administration of imaging agent
– Im... | healthcap.... |
| - | First Patient Dosed in Fusion Phase I trial. | Boston, Massachusetts & Hamilton, Ontario. February 19, 2019. Seroba portfolio company, Fusion P... | seroba-lif... |
| - | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed... |
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-parti... | healthcap.... |
| - | Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Ch... | Boston, MA & Hamilton, ON – March 23, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncol... | healthcap.... |
| - | Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D... | Hamilton, ON and Boston. April 1, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage... | seroba-lif... |
| - | Fusion Pharmaceuticals Completes Oversubscribed Series A Fin... | HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical c... | healthcap.... |
| - | Fusion Pharmaceuticals Announces Research Collaboration With... | HAMILTON, Ontario and BOSTON, Jan. 11, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN... | healthcap.... |
| - | Fusion Pharmaceuticals Announces Investment From Canada Pens... | Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage pre... | healthcap.... |
| - | Fusion Pharmaceuticals Announces Preliminary Safety and Dosi... | Hamilton, Ontario and Boston. June 14, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-... | seroba-lif... |
| - | Fusion Pharmaceuticals And Niowave Announce Actinium-225 Col... | HAMILTON, ON and BOSTON and LANSING, Mich., June 10, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc.... | healthcap.... |
| - | Fusion Pharmaceuticals Appoints New Chief Medical Officer | Hamilton, Ontario. 23 March 2020. Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinica... | seroba-lif... |
| - | Fusion Pharmaceuticals Announces Appointment Of John J. Crow... | BOSTON, MA and HAMILTON, ONTARIO, March 4, 2019 – Fusion Pharmaceuticals, a clinical-stage biopharma... | healthcap.... |
| - | Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase... | Hamilton, Ontario and Boston. 10 December 2020. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinic... | seroba-lif... |
| - | Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financi... | – Company is advancing first targeted alpha therapy (TAT) candidate under collaboration with AstraZe... | healthcap.... |
| - | Fusion Pharmaceuticals Announces Investment from Canada Pens... | Hamilton, Ontario & Boston, Massachusetts. January 13, 2020. Seroba’s portfolio company, Fusion ... | seroba-lif... |
| - | Fusion Pharmaceuticals Announces Clinical Collaboration with... | Hamilton, Canada and Boston, USA. May 6, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinica... | seroba-lif... |
| - | Fusion Pharmaceuticals Announces Nomination Of First Targete... | Candidate Combines Fusion’s Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific A... | healthcap.... |
| - | Fusion Raises $105m in Series B Financing. | Hamilton, Ontario and Dublin, Ireland. April 2nd 2019. Seroba’s portfolio company, Fusion Pharmaceut... | seroba-lif... |
| - | Fusion Pharmaceuticals Announces Research Collaboration With... | HAMILTON, ON and BOSTON, Jan. 11, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a ... | healthcap.... |
| - | Fusion Pharmaceuticals Announces FDA Clearance of IND for FP... | Hamilton, Ontario and Boston, Massachusetts. July 28, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUS... | seroba-lif... |
| - | Fusion Pharmaceuticals Announces First Quarter 2022 Financia... | Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022
Company continues t... | healthcap.... |
| - | Fusion Pharmaceuticals Launches with a $25M USD Series A Fin... | HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical compa... | healthcap.... |
| - | Fusion Pharmaceuticals To Present At The 2022 Bloom Burton &... | HAMILTON, ON and BOSTON, April 26, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a... | healthcap.... |
| - | Fusion Pharmaceuticals To Present At The 38th Annual J.P. Mo... | Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, cl... | healthcap.... |
| - | Fusion Pharmaceuticals Announces FDA Clearance Of IND For FP... | HAMILTON, ON and BOSTON, June 23, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a ... | healthcap.... |
| - | Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. t... | Boston, Massachusetts & Hamilton, Ontario. February 6, 2020. Seroba’s portfolio company, Fusion ... | seroba-lif... |
| - | Fusion Pharmaceuticals Appoints Industry Veteran Christopher... | Hamilton, Canada and Boston, USA. 2 November 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a cli... | seroba-lif... |
| - | Fusion Pharmaceuticals Announces Collaboration With AstraZen... | Hamilton, Ontario and Boston, 2 November 2020. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinica... | seroba-lif... |
